Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
shingles
Biotech
Moderna winds down 3 mRNA programs
Moderna has binned three more clinical mRNA programs as it aims to reduce its R&D spend.
Gabrielle Masson
Nov 20, 2025 4:10pm
Dynavax's vaccine holds its own against Shingrix in early test
Aug 21, 2025 8:00am
Curevo clinches $110M, nabs Moncef Slaoui to lead board
Mar 17, 2025 10:44am
Moderna touts 3 phase 1 data sets to bolster early vax work
Mar 27, 2024 3:21pm
Curevo’s shingles vaccine equals Shingrix in ph. 2 head-to-head
Jan 8, 2024 9:44am
Curevo will go head-to-head against GSK's Shingrix with $60M
Feb 10, 2022 11:25am
